IPR decision: May 29, 2020
|
AIA Review #
|
Filing Date
|
Institution Decision Date
|
Petitioner
|
Patent
|
Respondent
|
Status
|
|
IPR2019-00207
|
11/06/2018
|
05/10/2019
|
Amneal
|
9,517,219
|
Almirall LLC
|
All Challenged Claims Unpatentable
|
|
IPR2019-01095
|
06/07/2019
|
11/27/2019
|
Mylan
|
9,517,219
|
Almirall LLC
|
All Challenged Claims Unpatentable
|
US 9,517,219 (Allergan, Inc.; Exp: 11/18/2033)
1. A method for treating a dermatological condition selected from the group consisting of acne vulgaris and rosacea comprising administering to a subject having the dermatological condition selected from the group consisting of acne vulgaris and rosacea a topical pharmaceutical composition comprising: about 7.5% w/w dapsone; about 30% w/w to about 40% w/w diethylene glycol monoethyl ether; about 2% w/w to about 6% w/w of a polymeric viscosity builder comprising acrylamide/sodium acryloyldimethyl taurate copolymer; and water; wherein the topical pharmaceutical composition does not comprise adapalene.
6. A method for treating a dermatological condition selected from the group consisting of acne vulgaris and rosacea comprising administering to a subject having the dermatological condition selected from the group consisting of acne vulgaris and rosacea a topical pharmaceutical composition comprising: about 7.5% w/w dapsone; about 30% w/w diethylene glycol monoethyl ether; about 4% w/w of a polymeric viscosity builder comprising acrylamide/sodium acryloyldimethyl taurate copolymer; and water; wherein the topical pharmaceutical composition does not comprise adapalene.
Leave a Reply